200 related articles for article (PubMed ID: 35603156)
21. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.
Ligon JA; Choi W; Cojocaru G; Fu W; Hsiue EH; Oke TF; Siegel N; Fong MH; Ladle B; Pratilas CA; Morris CD; Levin A; Rhee DS; Meyer CF; Tam AJ; Blosser R; Thompson ED; Suru A; McConkey D; Housseau F; Anders R; Pardoll DM; Llosa N
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021032
[TBL] [Abstract][Full Text] [Related]
22. Applying Osteosarcoma Immunology to Understand Disease Progression and Assess Immunotherapeutic Response.
Pratt HG; Justin EM; Lindsey BA
Adv Exp Med Biol; 2020; 1258():91-109. PubMed ID: 32767236
[TBL] [Abstract][Full Text] [Related]
23. A Hypoxia Gene-Based Signature to Predict the Survival and Affect the Tumor Immune Microenvironment of Osteosarcoma in Children.
Jiang F; Miao XL; Zhang XT; Yan F; Mao Y; Wu CY; Zhou GP
J Immunol Res; 2021; 2021():5523832. PubMed ID: 34337075
[TBL] [Abstract][Full Text] [Related]
24. A CIC-related-epigenetic factors-based model associated with prediction, the tumor microenvironment and drug sensitivity in osteosarcoma.
Yu B; Geng C; Wu Z; Zhang Z; Zhang A; Yang Z; Huang J; Xiong Y; Yang H; Chen Z
Sci Rep; 2024 Jan; 14(1):1308. PubMed ID: 38225273
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Factors in Patients With Osteosarcoma With the Surveillance, Epidemiology, and End Results Database.
Fu P; Shi Y; Chen G; Fan Y; Gu Y; Gao Z
Technol Cancer Res Treat; 2020; 19():1533033820947701. PubMed ID: 32787692
[TBL] [Abstract][Full Text] [Related]
26. Development of an immune-related signature for predicting survival outcome and immunotherapy response in osteosarcoma.
Wang Q; Zhang W; Guo Y; Li Y; Fu K
Aging (Albany NY); 2021 Nov; 13(21):24155-24170. PubMed ID: 34747719
[TBL] [Abstract][Full Text] [Related]
27. New Horizons in the Treatment of Osteosarcoma.
Meltzer PS; Helman LJ
N Engl J Med; 2021 Nov; 385(22):2066-2076. PubMed ID: 34818481
[No Abstract] [Full Text] [Related]
28. Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma.
Tian Q; Gao H; Zhao W; Zhou Y; Yang J
Future Oncol; 2021 Nov; 17(31):4115-4129. PubMed ID: 34291650
[TBL] [Abstract][Full Text] [Related]
29. Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study.
Urakawa H; Nishida Y; Naruse T; Nakashima H; Ishiguro N
Clin Orthop Relat Res; 2009 Nov; 467(11):2932-8. PubMed ID: 19326179
[TBL] [Abstract][Full Text] [Related]
30. Development and validation of a pretreatment prognostic index to predict death and lung metastases in extremity osteosarcoma.
Wang B; Tu J; Yin J; Zou C; Wang J; Huang G; Xie X; Shen J
Oncotarget; 2015 Nov; 6(35):38348-59. PubMed ID: 26435480
[TBL] [Abstract][Full Text] [Related]
31. p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities: an analysis of 357 cases.
Righi A; Gambarotti M; Sbaraglia M; Sisto A; Ferrari S; Dei Tos AP; Picci P
Hum Pathol; 2016 Dec; 58():15-23. PubMed ID: 27544803
[TBL] [Abstract][Full Text] [Related]
32. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials.
Livingston JA; Hess KR; Naing A; Hong DS; Patel S; Benjamin RS; Ludwig JA; Conley A; Herzog CE; Anderson P; Meric-Bernstam F; Kurzrock R; Subbiah V
Oncotarget; 2016 Sep; 7(39):64421-64430. PubMed ID: 27486883
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of histological response to chemotherapy in osteosarcoma patients receiving tumor-bearing frozen autograft.
Miwa S; Takeuchi A; Ikeda H; Shirai T; Yamamoto N; Nishida H; Hayashi K; Tanzawa Y; Kimura H; Igarashi K; Tsuchiya H
PLoS One; 2013; 8(8):e71362. PubMed ID: 23977028
[TBL] [Abstract][Full Text] [Related]
34. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients.
Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jeon DG
Ann Surg Oncol; 2008 Mar; 15(3):906-14. PubMed ID: 18163171
[TBL] [Abstract][Full Text] [Related]
35. Construction and validation of nomogram to predict distant metastasis in osteosarcoma: a retrospective study.
Lu S; Wang Y; Liu G; Wang L; Wu P; Li Y; Cheng C
J Orthop Surg Res; 2021 Mar; 16(1):231. PubMed ID: 33785046
[TBL] [Abstract][Full Text] [Related]
36. Development and Validation of Prognostic Nomograms for Elderly Patients with Osteosarcoma.
Liu X; He S; Yao X; Hu T
Int J Gen Med; 2021; 14():5581-5591. PubMed ID: 34548809
[TBL] [Abstract][Full Text] [Related]
37. A risk signature-based on metastasis-associated genes to predict survival of patients with osteosarcoma.
Shi Y; He R; Zhuang Z; Ren J; Wang Z; Liu Y; Wu J; Jiang S; Wang K
J Cell Biochem; 2020 Jul; 121(7):3479-3490. PubMed ID: 31898371
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy for osteosarcoma: Where do we go from here?
Wedekind MF; Wagner LM; Cripe TP
Pediatr Blood Cancer; 2018 Sep; 65(9):e27227. PubMed ID: 29923370
[TBL] [Abstract][Full Text] [Related]
39. Osteosarcoma immune prognostic index can indicate the nature of indeterminate pulmonary nodules and predict the metachronous metastasis in osteosarcoma patients.
He X; Lu M; Hu X; Li L; Zou C; Luo Y; Zhou Y; Min L; Tu C
Front Oncol; 2022; 12():952228. PubMed ID: 35936683
[TBL] [Abstract][Full Text] [Related]
40. A Four-Pseudogene Classifier Identified by Machine Learning Serves as a Novel Prognostic Marker for Survival of Osteosarcoma.
Liu F; Xing L; Zhang X; Zhang X
Genes (Basel); 2019 May; 10(6):. PubMed ID: 31146489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
